Design Therapeutics, Inc.
DSGN
$4.75
$0.0250.53%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Net Income | -4.69% | -10.57% | -6.20% | 6.22% | 25.00% |
Total Depreciation and Amortization | -2.61% | 1.32% | 5.59% | 3.62% | 0.73% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 22.07% | -3.87% | 18.74% | 63.16% | -41.17% |
Change in Net Operating Assets | -3.88% | 224.41% | 54.06% | -47.66% | -396.75% |
Cash from Operations | -3.29% | 15.22% | 9.48% | 2.81% | 11.94% |
Capital Expenditure | -100.00% | 109.94% | 17.44% | -622.22% | 49.06% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 131.36% | -121.25% | 32.11% | 272.82% | -63.56% |
Cash from Investing | 131.45% | -121.31% | 32.58% | 271.13% | -63.61% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | 26,200.00% | -99.56% | 1,045.00% | -96.01% | 3,753.85% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | 26,200.00% | -99.56% | 1,045.00% | -96.01% | 3,753.85% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 49.48% | -194.29% | 98.88% | 221.58% | -1,004.97% |